Recombinant human interleukin-1 receptor antagonist (General Regeneratives)

重组人白介素-1受体拮抗剂（交晨生物医药）

Report date: 2026/03/23 20:03:44

Base Information

Drug NameRecombinant human interleukin-1 receptor antagonist (General Regeneratives)
Drug Alias NamerhIL-1ra (General Regeneratives)GR-007UA007
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInterleukin-1 receptor antagonists
TargetsInterleukin-1 receptor
Therapy Area/IndicationsDrug-Related Side Effects and Adverse ReactionsDiarrheaArthritis, Gouty +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiaochen Biological Medicine Technology (Shanghai) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesJiaochen Biological Medicine Technology (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsDiarrheaArthritis, GoutyColorectal Neoplasms
Inactive IndicationsDrug-Related Side Effects and Adverse Reactions

Other Information

ATC CodeN/A
Related LinksN/A